TMPRSS6 RNAi Oligonucleotides for Iron Overload Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatment options for iron overload disorders such as hereditary hemochromatosis and beta-thalassemia are limited, and there is a need for effective methods to manage iron homeostasis and prevent complications like liver cirrhosis and diabetes.

Innovation Solution

Development of RNAi oligonucleotides that target and reduce TMPRSS6 expression, thereby increasing hepcidin levels and reducing serum iron levels, using specific sense and antisense strands with complementary regions and modifications to enhance efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatment options are used for iron overload disorders, then treatment is limited and ineffective, but developing new RNAi oligonucleotides increases treatment complexity and cost

Engineering Contradiction:

Improveeffectiveness of iron overload treatmentVSAvoidcomplexity of RNAi oligonucleotide therapy

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses RNAi oligonucleotides as intermediary molecules to mediate between the administered therapy and the TMPRSS6 target. These oligonucleotides contain sense and antisense strands that hybridize to form duplexes, which then interact with TMPRSS6 mRNA to inhibit its translation. This intermediary mechanism provides a controlled and specific way to reduce TMPRSS6 expression and increase hepcidin levels, thereby treating iron overload disorders effectively while managing the complexity through standardized oligonucleotide design platforms.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If RNAi oligonucleotides are designed with specific modifications to enhance efficacy, then therapeutic effectiveness improves, but manufacturing complexity and cost increase

Engineering Contradiction:

Improvetherapeutic effectiveness of RNAi oligonucleotidesVSAvoidease of manufacturing modified oligonucleotides

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent employs parameter changes by modifying the chemical structure of oligonucleotide components (sugar moieties, phosphate backbones, nucleobases) to optimize therapeutic effectiveness. Specific modifications include 2'-O-methyl ribose, phosphorothioate linkages, and locked nucleic acid (LNA) modifications. These parameter changes enhance stability, binding affinity, and cellular uptake while the patent provides systematic methods for incorporating these modifications during solid-phase synthesis, balancing improved efficacy with manufacturability through standardized synthetic protocols.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If TMPRSS6 expression is strongly inhibited to increase hepcidin levels, then iron overload is better controlled, but risk of iron deficiency and other complications increases

Engineering Contradiction:

Improvecontrol of iron overloadVSAvoidrisk of iron deficiency and organ damage

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent implements feedback control by designing RNAi oligonucleotides that selectively inhibit TMPRSS6 expression, which normally suppresses hepcidin production. By reducing TMPRSS6 levels, the therapy creates a feedback loop where increased hepcidin levels subsequently regulate iron absorption and distribution. The feedback mechanism naturally adjusts iron homeostasis - when iron levels are high, hepcidin increases to block ferroportin and reduce iron release; when iron levels normalize, the effect diminishes. This feedback-based approach provides controlled iron overload management while minimizing the risk of iron deficiency through physiological self-regulation.

Inventive Principle:

Principle #23Feedback

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The RNAi oligonucleotides effectively decrease serum iron levels and iron saturation, providing a therapeutic approach to manage iron overload disorders by increasing hepcidin expression and preventing organ damage.

Implementation Method 1

RNAi oligonucleotides that target and reduce TMPRSS6 expression

Methodology Applied

Scientific EffectRNA interference (RNAi):

Implementation Method 2

antisense strand comprises a region of complementarity to a TMPRSS6 mRNA target sequence

Methodology Applied

Scientific EffectComplementary base pairing:

Data Source

PatentUS12503701B2Compositions and methods for inhibiting transmembrane serine protease 6 (TMPRSS6) expression

Publication Date: 2025.12.23 NOVO NORDISK AS

AI summary

Oligonucleotides are provided herein that inhibit TMPRSS6 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with hepcidin deficiency or suppression.